背景:这项研究旨在证明使用hinotori™手术机器人系统进行机器人胃切除术的可行性和安全性(MedicaroidCorporation,神户,日本)。
方法:我们回顾性纳入了2023年6月至2024年1月在我院接受了hinotori™手术机器人系统胃切除术治疗胃癌的16例患者。主治医生做了几乎所有的淋巴结切除术,包括船只的剪裁。助理外科医生使用血管密封装置和重建期间支持淋巴结清扫术。
结果:13例患者为cI期,一名患者为CII期,两名患者为CIII期。远端胃切除术,近端胃切除术,11、1和4例患者进行了全胃切除术,分别。11例和5例患者行D1+和D2淋巴结切除术,分别。Billroth-I,Billroth-II,Roux-en-Y,食管胃造口术在三个人中进行,六,六,还有一个病人,分别。中位手术时间为282(245-338)min,中位控制台时间为226(185-266)分钟。中位失血量为28(12-50)mL,术后第1天引流液中的淀粉酶中位数为280(148-377)U/L,术后第3天为74(42-148)U/L。一名接受近端胃切除术的患者出现吻合口漏(Clavien-Dindo[CD]IIIa)。术后中位住院时间为12.5(12-14)天。
结论:在此初始案例系列中,hinotori™手术机器人系统对胃癌患者是安全可行的,建议适合胃切除术,包括远端胃切除术和全胃切除术。
BACKGROUND: This study aims to prove the feasibility and safety of robotic gastrectomy using the hinotori™ Surgical Robot System (Medicaroid Corporation, Kobe, Japan).
METHODS: We retrospectively enrolled the 16 patients who underwent gastrectomy by the hinotori™ Surgical Robot System for gastric cancer at our hospital between June 2023 and January 2024. Console surgeons performed almost all lymphadenectomies, including the clipping of vessels. Assistant surgeons supported the lymphadenectomy using vessel sealing devices and during reconstruction.
RESULTS: Thirteen patients were cStage I, one patient was cStage II, and two patients were cStage III. Distal gastrectomy, proximal gastrectomy, and total gastrectomy were performed in 11, 1, and 4 patients, respectively. D1+ and D2 lymphadenectomies were performed in 11 and 5 patients, respectively. Billroth-I, Billroth-II, Roux-en-Y, and esophagogastrostomy were performed in three, six, six, and one patients, respectively. The median operation time was 282 (245-338) min, and the median console time was 226 (185-266) min. The median blood loss was 28 (12-50) mL, and the median amylase levels in drainage fluid were 280 (148-377) U/L on postoperative day 1 and 74 (42-148) U/L on postoperative day 3. There was anastomotic leakage (Clavien-Dindo [CD] IIIa) in one patient who underwent proximal gastrectomy. The median postoperative hospital stay was 12.5 (12-14) days.
CONCLUSIONS: In this initial case series, the hinotori™ Surgical Robot System was found to be safe and feasible for patients with gastric cancer and is suggested to be appropriate for gastrectomy, including distal gastrectomy and total gastrectomy.